The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Quality control (QC) review
National Library of Medicine (NLM) staff perform a limited review of submitted study records for apparent errors, deficiencies, or inconsistencies. NLM staff identify potential major and advisory issues and provide comments directly to the study sponsor or investigator. Major issues identified in QC review must be addressed or corrected (see First submitted that met QC criteria and Results first submitted that met QC criteria). Advisory issues are suggestions to help improve the clarity of the record. NLM staff do not verify the scientific validity or relevance of the submitted information. The study sponsor or investigator is responsible for ensuring that the studies follow all applicable laws and regulations.
https://clinicaltrials.gov/ct2/about-studies/glossary
Thanks kowalski, here it is summarised
https://noticias.r7.com/saude/coronavirus-estudo-com-coquetel-de-remedios-tem-bons-resultados-contra-a-covid-19-mostra-the-lancet-08052020
To date, early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.
https://www.thailandmedical.news/news/covid-19-drug-research-second-phase-of-clinical-trial-of-new-drug-candidate,-sng001-for-sars-cov-2-coronavirus-initiated
https://twitter.com/ProfWilko/status/1257060179746721792?s=20
https://twitter.com/UoSMedia/status/1255473196440190983?s=20
Prof Tom Wilkinson of
@UoS_Medicine
and
@RDsouthampton
will be clinical academic lead in a new national programme to accelerate the development of life-saving treatments for the most vulnerable #COVID19 patients.
When I posted the video link below here yesterday evening, it had just 521 views since the 21 April. Since posting here yesterday it has had more than 1100 views in less than 24 hr. The evidence is stacking quite substantially that Interferon B, and more importantly SNG's delivery method, is going to be a game changer.
In their data, the researchers also saw a surprising phenomenon -- expression of the ACE2 gene appeared to be correlated with activation of genes that are known to be turned on by interferon, a protein that the body produces in response to viral infection. To explore this further, the researchers performed new experiments in which they treated cells that line the airway with interferon, and they discovered that the treatment did indeed turn on the ACE2 gene.
https://www.sciencedaily.com/releases/2020/04/200422132556.htm
https://www.leicestersresearch.nhs.uk/about-us-2/covid-19-and-clinical-research/covid-19-trials/
Interesting tha Leicester are also involved within the adaptive study
This is an adaptive study, which means new therapies can be added to the trial as they become available.
https://www.leicestersresearch.nhs.uk/about-us-2/covid-19-and-clinical-research/covid-19-trials/
sorry wrong link previously
try this one https://www.scmp.com/news/hong-kong/health-environment/article/3079502/coronavirus-causes-covid-19-can-produce-more
Evidence is suggesting more and more that whatever treatment is going to be used, then Interrferon B shall be included proving more and more that Interferon beta is seriously the backbone when using other treatment methods.
For info: https://www.uhs.nhs.uk/AboutTheTrust/Newsandpublications/Latestnews/2020/April/Southampton-researchers-set-to-begin-COVID-19-vaccine-trials.aspx
treatment with both IFN-beta and IFN-gamma inhibited SARS-CoV plaque formation by 30-fold and replication by 3000-fold at 24 h and by > 1 x 10(5)-fold at 48 and 72 h post-infection. These studies suggest that combination IFN treatment warrants further investigation as a treatment for SARS.
https://twitter.com/ICMRDELHI/status/1251925596839395328?s=20
The virus is like a ninja, replicating inside the body with lower interferons and inflammatory response
The findings also proved that a ****tail therapy by Hong Kong medical practitioners is going in the right direction to induce an immune system response, Yuen added. Doctors have been prescribing a ****tail of lopinavir and ritonavir along with interferon beta
https://www.scmp.com/news/hong-kong/health-environment/article/3079502/coronavirus-causes-covid-19-can-produce-more